Table 1.
Demographic and clinical characteristics of subjects
| Characteristics | Remission group (n=31) | Nonremission group (n=54) | P-values |
|---|---|---|---|
| Demographic and diagnostic variables | |||
| Age (20–30 years/40–50 years/60–70 years) | 6/16/9 (19.4%/51.6%/29.0%) | 15/25/14 (27.8%/46.3%/25.9%) | P=0.687 |
| Sex (men/women) | 15/16 (48.4%/51.6%) | 23/31 (42.6%/57.4%) | P=0.601 |
| Diagnosis (MD/BD) | 22/9 | 49/5 | P=0.031* |
| Comorbid anxiety disorders, n (%) | 1 (3.2%) | 12 (22.2%) | P=0.026* |
| Psychiatric medication variables | |||
| Class of antidepressant (SSRI or SNRI/TCA/both) | 17/3/11 | 34/4/16 | P=0.759 |
| Final dose of aripiprazole, >3 mg, n (%) | 13 (41.9%) | 31 (57.4%) | P=0.169 |
| Premedication of other AAs, n (%) | 10 (32.3%) | 18 (33.3%) | P=0.919 |
| Clinical variables | |||
| Severity (moderate group/severe group) | 24/7 | 42/12 | P=1.000 |
| Number of recurrent major depressive episodes, >3, n (%) | 10 (32.3%) | 13 (24.1%) | P=0.454 |
| Lack of response to antidepressant therapy, >2, n (%) | 18 (58.1%) | 24 (44.4%) | P=0.227 |
| Duration of current episode, <3 months, n (%) | 1 (3.2%) | 9 (16.07%) | P=0.085 |
Note:
*
P<0.05.
Abbreviations: AAs, atypical antipsychotics; BD, bipolar disorder; MD, major depressive disorder; SNRI, serotonin–noradrenalin reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant.